Status:
COMPLETED
Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.
Eligibility Criteria
Inclusion
- Healthy males and healthy females according to the assessment of the Investigator.
- Body mass index of 18.0 kg/m\^2 through 32.0 kg/m\^2, inclusive, and body weight ≥ 50 kg.
Exclusion
- Any significant acute or chronic medical illness.
- Current or recent (within 3 months of first dose) gastrointestinal (GI) disease that could possibly affect drug absorption, distribution, metabolism, and excretion.
- History of any significant drug allergy.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
October 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 13 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06566768
Start Date
October 7 2024
End Date
June 13 2025
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Nottingham, Nottinghamshire, United Kingdom, NG11 6JS